Koers Diaxonhit Euronext Paris
Aandelen
FR0004054427
Biotechnologie & Medisch Onderzoek
Omzet 2023 | 130 mln. 141 mln. | Omzet 2024 * | 138 mln. 150 mln. | Marktkapitalisatie | 150 mln. 163 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 | 4 mln. 4,34 mln. | Nettowinst (verlies) 2024 * | 9 mln. 9,77 mln. | EV/omzet 2023 | 1,29 x |
Nettoschuld 2023 * | 23 mln. 24,97 mln. | Nettoliquiditeiten 2024 * | 9,9 mln. 10,75 mln. | EV/omzet 2024 * | 1,01 x |
K/w-verhouding 2023 |
38,3
x | K/w-verhouding 2024 * |
15,4
x | Werknemers | - |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 61,3% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 19-06-17 |
Director of Finance/CFO | 43 | 01-10-22 | |
Cathie Marsais
COO | Chief Operating Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 19-06-17 |
Director/Board Member | 68 | 04-11-09 | |
Director/Board Member | 67 | 15-06-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+41,79% | 50,93 mld. | |
-0,56% | 42,12 mld. | |
+49,62% | 42,05 mld. | |
-7,20% | 29,18 mld. | |
+12,59% | 26,02 mld. | |
-21,51% | 18,9 mld. | |
+6,92% | 13,21 mld. | |
+24,91% | 12,17 mld. | |
+29,60% | 12,16 mld. |